Neuronetics Inc Cash Flow Conversion Efficiency
Neuronetics Inc cash flow conversion efficiency. Based on the latest financial reports, Neuronetics Inc (STIM) has a cash flow conversion efficiency ratio of -0.552x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.42 Million) by net assets ($17.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Neuronetics Inc (2016–2025)
Cash flow conversion efficiency of Neuronetics Inc from 2016 to 2025. This chart illustrates how Neuronetics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View STIM share price today for real-time trading data and today's change.
Neuronetics Inc Cash Flow Conversion Ratio Explained
Neuronetics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Neuronetics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neuronetics Inc ranked by their cash flow conversion efficiency. Also see STIM stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shree Digvijay Cement Co.Ltd
NSE:SHREDIGCEM
|
-0.145x |
|
Sao Ta Foods JSC
VN:FMC
|
0.089x |
|
OBOOK Holdings Inc. Class A Common Shares
NASDAQ:OWLS
|
0.386x |
|
TAT HONG EQ.SRV. DL-08
F:1Q2
|
N/A |
|
PJBumi Bhd
KLSE:7163
|
-0.050x |
|
Empress Royalty Corp
V:EMPR
|
0.125x |
|
Arla Plast AB
ST:ARPL
|
0.019x |
|
Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX
|
-0.125x |
Annual Cash Flow Conversion Efficiency for Neuronetics Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Neuronetics Inc from 2016 to 2025. Review STIM free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $26.24 Million | $-20.37 Million | -0.776x | +20.35% |
| 2024-12-31 | $31.80 Million | $-31.00 Million | -0.975x | -4.03% |
| 2023-12-31 | $34.19 Million | $-32.04 Million | -0.937x | -73.94% |
| 2022-12-31 | $57.06 Million | $-30.74 Million | -0.539x | -63.97% |
| 2021-12-31 | $85.17 Million | $-27.98 Million | -0.329x | +70.50% |
| 2020-12-31 | $25.49 Million | $-28.39 Million | -1.114x | -74.82% |
| 2019-12-31 | $47.85 Million | $-30.48 Million | -0.637x | -119.78% |
| 2018-12-31 | $71.04 Million | $-20.59 Million | -0.290x | -601.07% |
| 2017-12-31 | $-192.65 Million | $-11.14 Million | 0.058x | +19.96% |
| 2016-12-31 | $-177.12 Million | $-8.54 Million | 0.048x | -- |
About Neuronetics Inc
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a p… Read more